Eli Lilly said Thursday that its triple-agonist obesity drug retatrutide hit every primary and key secondary endpoint in TRIUMPH-1, the Phase 3 registration trial that will anchor the company's expected FDA filing
During the Ozempic and Wegovy shortages of 2023 and 2024, compounding pharmacies began producing their own versions of semaglutide and tirzepatide
#GLP1 #Pharma #Strategy #MarketAccess #PharmaGambit To view or add a comment, sign in AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS VESALIUS-CV Subgroup Results Show Repatha Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes New Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes Care THOUSAND OAKS, Calif., [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News To view or add a comment, sign in AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS VESALIUS-CV Subgroup Results Show Repatha Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes New Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes Care THOUSAND OAKS, Calif., [...] To view or add a comment, sign in Imagine telling a pharmacist in 2015: A diabetes drug will soon be used for weight loss, heart protection, kidney disease, fatty liver disease, and even sleep apnea. Most people would have laughed
An A1C of 6% corresponds to an average glucose of approximately 126 mg/dL
Peptides are most stable when stored in the original glass vial
Retatrutid se koristi kao nedeljna injekcija, odnosno on se ubrizgava u organizam jednom u 7 dana
